Core Insights - Option Care (OPCH) is currently viewed as a better value opportunity compared to Chemed (CHE) based on various financial metrics and analyst outlooks [1][3][7] Valuation Metrics - OPCH has a Zacks Rank of 1 (Strong Buy), while CHE has a Zacks Rank of 4 (Sell), indicating stronger earnings estimate revision activity for OPCH [3] - OPCH's forward P/E ratio is 20.38, compared to CHE's forward P/E of 24.24, suggesting OPCH is more attractively priced [5] - The PEG ratio for OPCH is 1.82, while CHE's PEG ratio is 2.37, indicating OPCH's expected earnings growth is more favorably priced [5] - OPCH has a P/B ratio of 4.18, significantly lower than CHE's P/B of 8.12, further supporting OPCH's valuation attractiveness [6] Investment Outlook - The combination of stronger estimate revision activity and more favorable valuation metrics positions OPCH as the superior choice for value investors at this time [7]

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth S ...

Option Care (OPCH) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this infusion and home care services company, should get reflected in its stock price. After all, empirical research shows a strong correl ...

Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Option Care (OPCH) and Chemed (CHE) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on ear ...

Have you been paying attention to shares of Option Care (OPCH) ? Shares have been on the move with the stock up 10.7% over the past month. The stock hit a new 52-week high of $34.57 in the previous session. Option Care has gained 46.4% since the start of the year compared to the 6.7% move for the Zacks Medical sector and the 4.2% return for the Zacks Medical - Outpatient and Home Healthcare industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't m ...

Group 1 - Option Care Health, Inc. (OPCH) has reached an important support level and is considered a good stock pick from a technical perspective due to a recent "golden cross" event [1] - A golden cross is a bullish technical chart pattern formed when a stock's short-term moving average, typically the 50-day, crosses above its longer-term moving average, usually the 200-day [2] - The golden cross pattern consists of three stages: a downtrend followed by a bottom, the crossover of moving averages indicating a trend reversal, and an upward price movement [3] Group 2 - OPCH has moved 5.7% higher over the last four weeks, indicating potential for a breakout [4] - The company is currently rated 2 (Buy) on the Zacks Rank, suggesting positive market sentiment [4] - Earnings expectations for OPCH have improved, with three upward revisions and no downward changes in the last 60 days, leading to an increase in the Zacks Consensus Estimate [4][5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) Commission file number: 001-11993 OPTION CARE HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 05-0489664 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☑ No ☐ (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015 (A ...

Financial Data and Key Metrics Changes - Revenue growth for Q4 2024 was reported at 19.7% compared to Q4 2023, driven by balanced performance across the portfolio [18][19] - Gross profit increased by 8.6% year-over-year, reflecting strong top-line growth [19] - Adjusted EBITDA for Q4 was $121.6 million, growing almost 9% year-over-year, while adjusted earnings per share reached $0.44, representing a 15.8% increase [21] - Full-year cash flow generation was $323 million, with $250 million allocated to share repurchases [22] Business Line Data and Key Metrics Changes - The acute therapy segment experienced high single-digit growth, despite earlier supply chain disruptions [19] - The company reported significant contributions from its rare and orphan therapies, which are part of its limited distribution portfolio [18][19] - The advanced practitioner model was highlighted as a key area for growth, with 15 sites currently operational and plans for expansion [12][100] Market Data and Key Metrics Changes - The company noted improvements in IV solution supply dynamics, which had previously constrained patient onboarding [8][28] - The competitive landscape has shifted, with some larger competitors exiting the market, allowing the company to capture additional market demand [30][31] Company Strategy and Development Direction - The company aims to continue investing in its national integrated network of compounding pharmacies and infusion suites to enhance local responsiveness [9][16] - The acquisition of Intramed Plus is expected to expand the company's footprint and enhance its advanced practitioner model [11][12] - The focus remains on delivering value to referral sources and driving top-line growth despite challenges from specific therapy dynamics [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the challenges posed by the Stelara dynamics, estimating a gross profit impact of $60 million to $70 million for 2025 [15][24] - The company anticipates continued earnings growth in 2025, supported by a balanced portfolio and strategic investments [15][16] - Management emphasized the importance of maintaining high-quality care and operational efficiency in a competitive environment [30][31] Other Important Information - The company has exhausted its prior share repurchase authorization, repurchasing $90 million in Q4, and has a new $500 million authorization approved by the Board [13][14] - The company is committed to enhancing its infusion suite network and expanding clinical capabilities to provide comprehensive care solutions [12][100] Q&A Session Summary Question: Acute therapy growth and competition - Management noted improved supply chain dynamics and a strong position to onboard new patients, despite competitive shifts in the market [28][30] Question: Adjusted EPS and long-term growth algorithm - Management indicated that adjusted EPS growth is expected to outpace adjusted EBITDA growth due to share repurchase efforts and M&A activities [35][36] Question: Q1 seasonality and guidance - Management acknowledged typical early Q1 disruptions but expressed confidence in stable revenue from chronic therapies [42][43] Question: Impact of Stelara and patient support - Management confirmed ongoing support for complex Stelara patients while reallocating resources to growth initiatives [46][47] Question: Intramed acquisition and margins - Management expressed optimism about improving Intramed's margins through integration and leveraging existing capabilities [52][54] Question: M&A strategy and market opportunities - Management stated that they are not capital constrained and are actively pursuing M&A opportunities that align with their strategic goals [58][61] Question: Biosimilars impact on guidance - Management indicated that the current year would not see a material impact from biosimilars on guidance [70] Question: Labor costs and recruitment - Management reported a strong position in recruiting and retaining talent, with effective strategies in place to manage labor costs [72][74] Question: Payer negotiations and Medicare Advantage - Management highlighted constructive relationships with payers and the value they provide in managing total cost of care [105][109] Question: SG&A growth and operational investments - Management discussed investments in operational infrastructure to support market opportunities, with SG&A as a percentage of revenue continuing to decline [111][113] Question: VYJUVEK product traction - Management noted that while VYJUVEK is a clinical success, its gross margin profile remains mid-single-digit due to high therapy costs [116]

Option Care Health (OPCH) Q4 2024 Earnings Call February 26, 2025 08:30 AM ET Company Participants Nicole Maggio - SVP & Corporate ControllerJohn Rademacher - CEO, President & DirectorMike Shapiro - Chief Financial OfficerLisa Gill - Managing DirectorConstantine Davides - Managing DirectorSarah Conrad - Global Investment Research Associate Conference Call Participants Matt Larew - Research Analyst - HealthcareBrian Tanquilut - Equity Research Analyst - Healthcare ServicesPito Chickering - AnalystJoanna Gaju ...

Core Insights - Option Care (OPCH) reported quarterly earnings of $0.35 per share, exceeding the Zacks Consensus Estimate of $0.33 per share, and showing an increase from $0.32 per share a year ago, resulting in an earnings surprise of 6.06% [1] - The company achieved revenues of $1.35 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.56% and up from $1.12 billion year-over-year [2] - Option Care's stock has increased approximately 40.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.3% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.25 on revenues of $1.23 billion, while for the current fiscal year, the estimate is $1.26 on revenues of $5.35 billion [7] - The estimate revisions trend for Option Care is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Option Care belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]